Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-04-2011 | Short Communication

Paraneoplastic polymyositis associated with breast cancer: a therapeutic emergency

Authors: S. Croce, M. Guèye, A. C. E. Korganow, E. Chatelus, S. M. K. Guèye, P. Diemunsch, C. Mathelin

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Abstract

The association of polymyositis and cancer was first described in 1916, the most frequent cancers being mammary and gynecological for women, bronchopulmonary for men and digestive for both. This article reports a severe paraneoplastic polymyositis associated with breast cancer. The authors discuss its clinical, pathological and therapeutic particularities.
Literature
1.
Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9–13PubMedCrossRef
2.
Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12(2):R70PubMedCrossRef
3.
Toothaker TB, Rubin M (2009) Paraneoplastic neurological syndromes: a review. Neurologist 15(1):21–33PubMedCrossRef
4.
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRef
5.
Dalmau J, Gultekin HS, Posner JB (1999) Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 9(2):275–284PubMedCrossRef
6.
Sterz G (1916) Polymyositis. Berlin Klin Wochenschr 53:489
7.
Minisini AM, Pauletto G, Bergonzi P, Fasola G (2007) Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat 105(2):133–138PubMedCrossRef
8.
Anderson NE, Cunningham JM, Posner JB (1987) Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neurobiol 3(3):245–299PubMed
9.
Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, Graus F (2003) Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 82(3):216–223CrossRef
10.
Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, Delattre JY (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68(4):479–482PubMedCrossRef
11.
Verducci MA, Malkasian GD Jr, Friedman SJ, Winkelmann RK (1984) Gynecologic carcinoma associated with dermatomyositis-polymyositis. Obstet Gynecol 64(5):695–698PubMed
Metadata
Title
Paraneoplastic polymyositis associated with breast cancer: a therapeutic emergency
Authors
S. Croce
M. Guèye
A. C. E. Korganow
E. Chatelus
S. M. K. Guèye
P. Diemunsch
C. Mathelin
Publication date
01-04-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1328-7

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Preclinical study

Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-κB-dependent matrix metalloproteinase-9 expression

Letter to the Editor

Lymph node ratio, number of excised nodes and sentinel-node concepts in breast cancer

Letter to the Editor

Unincluded subjects need to be included for concerning the real association between TNFa-308 G/A polymorphism and cancer susceptibility

Epidemiology

A combined analysis of genome-wide association studies in breast cancer

Letter to the Editor

PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer

Epidemiology

Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits